5-(N,N-dimethyl)-Amiloride (hydrochloride): Benchmarking a Potent NHE1 Inhibitor for Cardiovascular and Endothelial Research

Executive Summary: 5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA) is a crystalline small molecule that potently inhibits the Na+/H+ exchanger isoforms NHE1 (Ki 0.02 µM), NHE2 (Ki 0.25 µM), and NHE3 (Ki 14 µM) under physiological conditions (APExBIO C3505). DMA’s selectivity enables precise modulation of intracellular pH and sodium ion balance in mammalian cells. It has demonstrated protective effects in cardiac ischemia-reperfusion models by normalizing sodium levels and preventing contractile dysfunction (Moesin biomarker study). The compound’s solubility (up to 30 mg/ml in DMSO or DMF) and rapid in vitro action streamline experimental workflows. DMA is a cornerstone for researchers investigating Na+/H+ exchanger signaling in cardiovascular, liver, and endothelial models.

Biological Rationale

The Na+/H+ exchanger (NHE) family maintains pH homeostasis and cell volume by exchanging intracellular H+ for extracellular Na+ ions. NHE1 is ubiquitously expressed in the plasma membrane of mammalian cells and is critical for the regulation of intracellular pH, sodium transport, and cell survival during stress. Dysregulated NHE1 activity contributes to pathological states including cardiac ischemia-reperfusion injury, vascular endothelial dysfunction, and multiple organ failure in sepsis. Moesin, a membrane-cytoskeleton linker protein, is upregulated during endothelial injury and correlates with NHE-driven sodium influx and tissue edema in sepsis (Chen et al., 2021).

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

DMA competitively inhibits Na+/H+ exchanger activity by binding to the extracellular domain of NHE1, NHE2, and NHE3. This blocks sodium uptake and proton extrusion, leading to intracellular acidification and reduced sodium accumulation. The Ki values for NHE1 (0.02 µM), NHE2 (0.25 µM), and NHE3 (14 µM) highlight DMA’s isoform selectivity. DMA has minimal effect on NHE4, NHE5, and NHE7 at experimental concentrations (<10 µM). This selectivity allows researchers to dissect NHE1/2/3 functions without off-target interference. DMA also inhibits ouabain-sensitive ATP hydrolysis and Na+/K+-ATPase activity in rat liver membranes, indicating broader roles in ion transport and metabolism (APExBIO).

Evidence & Benchmarks

• DMA inhibits NHE1 with a Ki of 0.02 µM, providing sub-micromolar control over pH regulation in mammalian cells (APExBIO).
• DMA administration in cardiac ischemia-reperfusion models normalizes tissue sodium levels and prevents contractile dysfunction (Chen et al., 2021).
• DMA reduces alanine uptake and Na+/K+-ATPase activity in rat hepatocytes, revealing effects on hepatic ion and metabolite transport (APExBIO).
• Moesin levels increase during sepsis-induced endothelial injury, paralleling NHE activation and suggesting a mechanistic link between sodium-proton exchange and endothelial dysfunction (Chen et al., 2021).
• DMA’s potency and selectivity were validated in cell-based assays and animal models at 37°C, pH 7.4, confirming robust inhibition of NHE-driven sodium flux (Thieno-GTP review).

Applications, Limits & Misconceptions

DMA is a reference Na+/H+ exchanger inhibitor in cardiovascular disease research, especially in studies of ischemia-reperfusion injury and intracellular pH modulation. Its selectivity for NHE1/2/3 supports precise experimental manipulation in endothelial, hepatic, and cardiac models. The compound is not recommended for clinical or diagnostic use and is restricted to in vitro and preclinical research.

This article extends prior APExBIO coverage by providing mechanistic detail and benchmarking data for DMA, improving upon the workflow focus in Optimizing Cell Assays with 5-(N,N-dimethyl)-Amiloride (hydrochloride) by clarifying ion transport mechanisms and translational endpoints. For a comparison of DMA’s selectivity versus other NHE inhibitors, see 5-(N,N-dimethyl)-Amiloride Hydrochloride: A Powerful NHE1 Inhibitor, which this article updates with recent evidence about endothelial biomarkers and sepsis models.

Common Pitfalls or Misconceptions

• DMA is not effective against all NHE isoforms: NHE4, NHE5, and NHE7 are minimally affected at standard concentrations (<10 µM).
• DMA is not suitable for long-term solution storage: Solutions degrade over time at room temperature; use immediately after preparation.
• Not for clinical use: DMA is for research only and not approved for therapeutic or diagnostic purposes.
• Off-target effects at high concentrations: Doses above 20 µM may inhibit other ion transporters and cellular targets.
• Isoform cross-reactivity in non-mammalian systems: Potency and selectivity may differ in non-mammalian or highly divergent cell types.

Workflow Integration & Parameters

DMA is soluble up to 30 mg/ml in DMSO or DMF and should be aliquoted and stored at -20°C. For in vitro assays, typical working concentrations are 0.01–10 µM, depending on the NHE isoform targeted. Solutions should be freshly prepared before use to ensure activity. APExBIO provides detailed protocols and purity specifications for batch-to-batch consistency (product page).

This article clarifies best practices for DMA deployment in comparison to the workflow-centric guidance in 5-(N,N-dimethyl)-Amiloride: Optimizing Na+/H+ Exchanger Inhibition, by emphasizing quantitative parameters and isoform specificity.

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride (hydrochloride) is a cornerstone research tool for studying sodium-proton exchange, intracellular pH regulation, and cardiovascular injury. Its potency, selectivity, and robust solubility support rigorous, reproducible research across cellular and animal models. The mechanistic linkage between NHE inhibition, endothelial resilience, and biomarkers such as moesin positions DMA as a critical reagent for the next generation of translational studies in cardiovascular and sepsis research (Chen et al., 2021). For full specifications and ordering, visit the APExBIO C3505 product page.